<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35114">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872520</url>
  </required_header>
  <id_info>
    <org_study_id>PekingUTH-Pharmacy-001</org_study_id>
    <nct_id>NCT01872520</nct_id>
  </id_info>
  <brief_title>Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study</brief_title>
  <official_title>Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suodi ZHAI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Greenvalley Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <authority>China: State Administration of Traditional Chinese Medicine of the People's Republic of China</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium Lithospermate B, the main constituent of the Injection of DanShenDuoFenSuanYan
      (the Injection of Depsides Salts From Salvia Miltiorrhiza), is the active ingredient of
      Salvia Miltiorrhiza. This study record clinical use of The injection of DanShenDuoFenSuanYan
      in the real world, and observe the adverse drug reactions/ adverse drug events during
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a traditional chinese medicine, the Injection of DanShenDuoFenSuanYan (the Injection of
      Depsides Salts From Salvia Miltiorrhiza) was approved by State Food and Drug Administration
      of China in May,2005. This cardiovascular drug is one of the few Traditional Chinese
      Medicine pharmaceuticals where the active ingredients have been identified in the molecular
      levels. In its 8 years marketing in China, there is no serious adverse drug reactions.

      In this study, clinical pharmacists in selected hospitals will record the clinical use and
      the adverse drug reactions/ adverse drug events of this injection.

      This real world study for the Injection of DanShenDuoFenSuanYan with 30400 patients will be
      conducted from June.2012 to May.2014.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>The adverse reaction rate to the Injection of DanShenDuoFenSuanYan</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The rare adverse drug reactions to the Injection of DanShenDuoFenSuanYan</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30400</enrollment>
  <condition>Adverse Drug Reaction</condition>
  <arm_group>
    <arm_group_label>the Injection of DanShenDuoFenSuanYan</arm_group_label>
    <description>Patient who use the Injection of DanShenDuoFenSuanYan</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in china(including
        the inpatient and the outpatient(only in some hospitals which can get the information))
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in
             china(including the inpatient and the outpatient(only in some hospitals which can get
             the information)).

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suodi ZHAI</last_name>
    <phone>+8615611908515</phone>
    <email>zhaisuodi@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking university third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suodi ZHAI, B.S.</last_name>
      <phone>+8615611908515</phone>
      <email>zhaisuodi@163.com</email>
    </contact>
    <investigator>
      <last_name>Suodi ZHAI, B.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 5, 2013</lastchanged_date>
  <firstreceived_date>April 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Suodi ZHAI</investigator_full_name>
    <investigator_title>Suodi ZHAI, Department of Pharmacy, Peking University Third Hospital</investigator_title>
  </responsible_party>
  <keyword>the Injection of DanShenDuoFenSuanYan</keyword>
  <keyword>Magnesium Lithospermate B</keyword>
  <keyword>Safety</keyword>
  <keyword>Real World Study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Drug Toxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lithospermate B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
